Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity
The peptide hormone ghrelin is the endogenous ligand for the type 1a growth hormone secretagogue receptor (GHS-R1a) and the only currently known circulating appetite stimulant. GHS-R1a antagonism has therefore been proposed as a potential approach for obe
Rudolph, Joachim,Esler, William P.,O'Connor, Stephen,Coish, Philip D. G.,Wickens, Philip L.,Brands, Michael,Bierer, Donald E.,Bloomquist, Brian T.,Bondar, Georgiy,Chen, Libing,Chuang, Chih-Yuan,Claus, Thomas H.,Fathi, Zahra,Fu, Wenlang,Khire, Uday R.,Kristie, James A.,Liu, Xiao-Gao,Lowe, Derek B.,McClure, Andrea C.,Michels, Martin,Ortiz, Astrid A.,Ramsden, Philip D.,Schoenleber, Robert W.,Shelekhin, Tatiana E.,Vakalopoulos, Alexandras,Tang, Weifeng,Wang, Lei,Yi, Lin,Gardell, Stephen J.,Livingston, James N.,Sweet, Laurel J.,Bullock, William H.
p. 5202 - 5216
(2008/03/12)
QUINAZOLINONE DERIVATIVES USEFUL FOR THE REGULATION OF GLUCOSE HOMEOSTASIS AND FOOD INTAKE
This invention relates to substituted quinazolinone derivatives, compositions, and methods for treating diabetes, obesity and related disorders, and regulation of food intake (e.g., stimulation and suppression).
-
Page/Page column 67
(2010/10/19)
More Articles about upstream products of 875269-92-4